Insight into Novel Treatment for Cognitive Dysfunctions across Disorders
Insight into Novel Treatment for Cognitive Dysfunctions across Disordershttps://www.damonapharma.com/wp-content/uploads/2020/04/article-image6.png1920800Etienne SibilleEtienne Sibillehttps://secure.gravatar.com/avatar/31fca8d52a9ddc2456d689e55abc91df?s=96&d=mm&r=g
Cognitive dysfunctions and development of treatment to alleviate them represent the main focus of Alpha CogTM. In this article, Drs. Prevot, Li, Cook and Sibille present how their research contribute to the discovery of novel small molecules that can participate in the reduction of cognitive dysfunctions in mood disorders, or age-related diseases.
Cognitive dysfunctions, including impaired attention, learning, memory, and problem solving, occur in psychiatric diseases, such as depression, and are a hallmark of aging. Altered GABAergic signaling is similarly reported across these conditions, but therapeutic approaches are limited by pan-receptor activities of benzodiazepine-like ligands. α5-GABA-A receptor-preferring ligands uncover novel therapeutics for cognitive dysfunctions.